Source: Xconomy

Stem CentRx: AbbVie Shares Plummet as $5.8B Bet on Stemcentrx Takes a Hit

There is still a chance that AbbVie's $5.8 billion gamble on acquiring Stemcentrx, a privately held developer of cancer stem cell drugs, could pay off. But the deal's prospects dimmed this morning with news that Stemcentrx's lead drug disappointed in clinical testing, sending shares of Chicago-based AbbVie down. AbbVie (NYSE: ABBV) said that it won't [...]

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Estimated Annual Revenue

Estimated Employees

Brian Slingerland's photo - Co-Founder & CEO of Stem CentRx

Co-Founder & CEO

Brian Slingerland

CEO Approval Rating


Stemcentrx researches, discovers, develops and commercializes therapies that cure and improve survival for cancer patien... Read more